20
Participants
Start Date
October 31, 2012
Primary Completion Date
February 28, 2014
Study Completion Date
February 28, 2014
BKM120
BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
Hospital Madrid Norte Sanchinarro- CIOCC, Madrid
Collaborators (1)
Novartis
INDUSTRY
Sofia Perea, Director Clinical Trials Unit.
OTHER